Gerresheimer stock faces margin pressure after Q3 revenue gain

Published on 11/09/2026 at 12:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gerresheimer stock traded at 31.08 euros on Lang & Schwarz at 12:06 CET on Monday, November 9, 2026, 0.38 percent below the November 6 Xetra close. Preliminary third-quarter revenue rose, while adjusted EBITDA margin narrowed.

Revenue grows, margins stay under pressure

Drug-delivery demand supported Gerresheimer's strongest operating division in the third quarter.
Management expects a stronger fourth quarter and kept its 2026 outlook unchanged.
The Primary Packaging Plastics disposal is expected to close in the first quarter of 2027.

Gerresheimer, DE000A0LD6E6, Illustration mit AI erstellt.

Gerresheimer stock traded at 31.08 euros on Lang & Schwarz at 12:06 CET on Monday, November 9, 2026, 0.38 percent below the Xetra close of 31.20 euros on Friday, November 6. The comparison is based on the Xetra closing price reported by boerse.de.

Gerresheimer released preliminary third-quarter and nine-month figures on October 30. According to the company's corporate release, third-quarter revenue increased 8 percent year over year to 605 million euros, including business units currently in the sales process. Adjusted EBITDA reached 103 million euros, compared with 106 million euros in the adjusted prior-year quarter.

Growth meets operational pressure

The adjusted EBITDA margin narrowed to 17.1 percent from 19.0 percent a year earlier. For the first nine months, revenue was broadly unchanged at 1.7 billion euros, while adjusted EBITDA fell to 272 million euros from 331 million euros. Gerresheimer attributed the decline to inventory reductions and weaker performance in Tubular Glass Europe and Moulded Glass.

Containment & Delivery Systems remained the main growth engine. Third-quarter revenue rose to 313 million euros from 286 million euros, while adjusted EBITDA increased to 77 million euros from 64 million euros. The division benefited from higher demand for drug-delivery devices and contributions from expanded production capacity.

Primary Injectable Solutions also increased quarterly revenue to 123 million euros from 114 million euros, driven mainly by Syringe Systems. Adjusted EBITDA declined to 15 million euros from 19 million euros, although the company described the business as stabilizing. Moulded Glass revenue rose to 169 million euros from 165 million euros, but adjusted EBITDA dropped to 17 million euros from 29 million euros as inventory reduction lowered capacity utilization.

Portfolio changes shape the outlook

Gerresheimer expects a stronger fourth quarter with further earnings improvement and said it remains within its 2026 guidance. The company completed the sale of Centor in October and is preparing the sale of its Primary Packaging Plastics business. Gerresheimer currently expects that transaction to close in the first quarter of 2027.

Management said the next milestones are the completion of the Primary Packaging Plastics sale and a comprehensive refinancing. The final third-quarter statement, including the final figures for the quarter and the first nine months, is scheduled for December 2026.

Investors can follow the real-time quote of Gerresheimer stock.

The broader German market can be followed through the DAX market overview.

More news and analyses are available on Gerresheimer stock.